"Smoke and Mirrors": Trump's Cannabis Rescheduling Order Falls Flat Amid Opposition
President Donald Trump's recent order to reschedule cannabis, a move that could potentially unlock more research opportunities and cut red tape for businesses and consumers, has turned out to be little more than a public relations stunt.
The Department of Justice was instructed to fast-track the process, but insiders now say that the outcome is far from certain. In fact, many are predicting a protracted and drawn-out battle over the fate of cannabis reform. The opposition within the administration and the conservative movement have already started gearing up for a fight against rescheduling.
The Controlled Substances Act, enacted by former President Richard Nixon, categorizes drugs into five schedules based on their potential for harm or addictiveness versus their medical use value. Schedule I substances are considered the most tightly controlled, with cannabis currently classified as such, alongside heroin and LSD.
Advocates of rescheduling argue that the current Schedule I classification is overly restrictive and hinders research and businesses in the industry. However, opponents like Attorney General Pam Bondi, a long-time opponent of cannabis reform, have vowed to drag the process out. The mechanisms within the administrative process allow for this delay, as noted by Paul Armentano, deputy director of NORML.
"I've been on the record for the last three years making it clear that this is designed to be a very long and drawn-out process," Armentano said. "History shows us that rescheduling petitions take multiple decades to resolve." The longest rescheduling petition on record took over 20 years to complete, from its initiation in 1972 until its resolution in 1994.
The current push for rescheduling dates back to 2022 when former President Joe Biden directed the Department of Health and Human Services to reexamine cannabis's scheduling status. However, despite Trump's recent order, the focus on rescheduling represents a double-edged sword for the industry.
Descheduling, or removing cannabis from Schedule I altogether, is seen by some as the more effective solution to regulatory barriers. Corey Coleman, co-founder of Sky High Brands and founder of the Iowa Hemp Coalition, highlights the arbitrary nature of cannabis regulation, which can benefit big business but hinder smaller operators.
"It's a step in the right direction," Coleman said. "But we still have a long way to go." As for Trump's order, it remains to be seen whether anything will actually change. A Justice Department official told Salon that they are working to identify the most expeditious means of executing the executive order, but many predict that rescheduling will take years – or even decades.
Ultimately, the outcome of this saga will depend on the actions of those within and outside the administration who are shaping the future of cannabis policy. For now, it's clear that the smoke has been blown, and the real work begins.
President Donald Trump's recent order to reschedule cannabis, a move that could potentially unlock more research opportunities and cut red tape for businesses and consumers, has turned out to be little more than a public relations stunt.
The Department of Justice was instructed to fast-track the process, but insiders now say that the outcome is far from certain. In fact, many are predicting a protracted and drawn-out battle over the fate of cannabis reform. The opposition within the administration and the conservative movement have already started gearing up for a fight against rescheduling.
The Controlled Substances Act, enacted by former President Richard Nixon, categorizes drugs into five schedules based on their potential for harm or addictiveness versus their medical use value. Schedule I substances are considered the most tightly controlled, with cannabis currently classified as such, alongside heroin and LSD.
Advocates of rescheduling argue that the current Schedule I classification is overly restrictive and hinders research and businesses in the industry. However, opponents like Attorney General Pam Bondi, a long-time opponent of cannabis reform, have vowed to drag the process out. The mechanisms within the administrative process allow for this delay, as noted by Paul Armentano, deputy director of NORML.
"I've been on the record for the last three years making it clear that this is designed to be a very long and drawn-out process," Armentano said. "History shows us that rescheduling petitions take multiple decades to resolve." The longest rescheduling petition on record took over 20 years to complete, from its initiation in 1972 until its resolution in 1994.
The current push for rescheduling dates back to 2022 when former President Joe Biden directed the Department of Health and Human Services to reexamine cannabis's scheduling status. However, despite Trump's recent order, the focus on rescheduling represents a double-edged sword for the industry.
Descheduling, or removing cannabis from Schedule I altogether, is seen by some as the more effective solution to regulatory barriers. Corey Coleman, co-founder of Sky High Brands and founder of the Iowa Hemp Coalition, highlights the arbitrary nature of cannabis regulation, which can benefit big business but hinder smaller operators.
"It's a step in the right direction," Coleman said. "But we still have a long way to go." As for Trump's order, it remains to be seen whether anything will actually change. A Justice Department official told Salon that they are working to identify the most expeditious means of executing the executive order, but many predict that rescheduling will take years – or even decades.
Ultimately, the outcome of this saga will depend on the actions of those within and outside the administration who are shaping the future of cannabis policy. For now, it's clear that the smoke has been blown, and the real work begins.